menu
    • menu
    [{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SP-624","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Not Applicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Orlando Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"SP-624","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Orlando Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Orlando Health Ventures"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SP-624","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Not Applicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RABI-767","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrivo BioVentures \/ Not Applicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SP-624","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrivo BioVentures \/ Not Applicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Arrivo BioVentures","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SP-624","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrivo BioVentures \/ Arrivo BioVentures","highestDevelopmentStatusID":"14","companyTruncated":"Arrivo BioVentures \/ Arrivo BioVentures"}]

    Find Clinical Drug Pipeline Developments & Deals by Arrivo BioVentures

    Menu

    Arrivo BioVentures

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Firefly Neuroscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Firefly Neuroscience Uses Brain Analytics Platform in Phase 1 SP-624 Study

                            Details : SP-624 is a first-in-class SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of patients with major depressive disorder.

                            Brand Name : SP-624

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 15, 2024

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Firefly Neuroscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arrivo Begins Phase 1 Study of SP-624 For Women with Major Depressive Disorder

                            Details : SP-624 is a novel SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of major depressive disorder.

                            Brand Name : SP-624

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 10, 2024

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RABI-767

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arrivo Gets FDA Fast Track for RABI-767 in Acute Pancreatitis

                            Details : RABI-767 is a novel, small molecule lipase inhibitor that halts the highly toxic cascade of fat necrosis, systemic toxicity, organ failure and mortality in severe acute pancreatitis.

                            Brand Name : RABI-767

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 15, 2024

                            Lead Product(s) : RABI-767

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arrivo Bio Initiates Phase 2b Clinical Trial for Major Depressive Disorder with SIRT6

                            Details : SP-624 is a novel SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of major depressive disorder.

                            Brand Name : SP-624

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 16, 2024

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Orlando Health Ventures

                            Deal Size : $45.2 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ArrivoBio Raises $45M in Series B Financing to Advance Pipeline

                            Details : Arrivo will advance its first-in-class treatment for major depressive disorder, SP-624, through Phase 2b/3 trial and complete a Phase 2 study with its novel treatment to prevent patients with pancreatitis advancing to severe acute pancreatitis, RABI-767.

                            Brand Name : SP-624

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2023

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Orlando Health Ventures

                            Deal Size : $45.2 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Arrivo BioVentures

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder

                            Details : SP-624 has a novel epigenetic mechanism to enhance neuroplasticity in brain regions involved in depression, namely the hippocampus and prefrontal cortex.

                            Brand Name : SP-624

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : SP-624

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth